Loss of expression of the cell-cell adhesion molecule E-cadherin is a hallmark of epithelial-mesenchymal transition (EMT) in development and in the progression from epithelial tumours to invasive and metastatic cancers. Here, we demonstrate that the loss of E-cadherin function upregulates expression of the neuronal cell adhesion molecule (NCAM). Subsequently, a subset of NCAM translocates from fibroblast growth factor receptor (FGFR) complexes outside lipid rafts into lipid rafts where it stimulates the non-receptor tyrosine kinase p59
Introduction
When cancer cells disseminate from a primary tumour and infiltrate the surrounding tissue, they leave the tumour mass not only by gaining migratory and invasive capabilities but also by dissolving cell-cell contacts, known as tight and adherens junctions (Friedl and Wolf, 2003) . Consistent with this notion, the calcium-dependent cell-cell adhesion molecule E-cadherin, the prototype adhesion molecule of epithelial adherens junctions, is found absent or dysfunctional in the majority of epithelial cancers (carcinomas) (Cavallaro and Christofori, 2004) . Inhibition of E-cadherin activity by specific neutralizing antibodies or shRNA-mediated downregulation of its expression in epithelial MDCK cells leads to increased motility and invasiveness (Behrens et al, 1989; Qin et al, 2005) . Conversely, the invasive behaviour of carcinoma cells can be blocked by forced expression of E-cadherin (Frixen et al, 1991) . Using a transgenic mouse model of pancreatic b-cell carcinogenesis (Rip1Tag2), we have demonstrated earlier that the loss of E-cadherin is a rate-limiting event during tumour progression (Perl et al, 1998) .
In many cancer types, the loss of E-cadherin coincides with a gain of expression of the mesenchymal cadherin, N-cadherin. This 'cadherin switch' is thought to be required for tumour cells to gain invasive properties (Cavallaro, 2004) . Interestingly, the cadherin switch is also a hallmark of epithelial-mesenchymal transition (EMT), a process characterized by the combined loss of epithelial cell junction proteins, including E-cadherin, a-catenin, b-catenin and claudins, and the gain of mesenchymal markers, such as N-cadherin, vimentin and fibronectin (Thiery, 2003; Thiery and Sleeman, 2006) . EMT is a critical process during embryonic development and it is thought to have an important function in the progression of cancer, although this hypothesis is still under debate (Lee et al, 2006) .
Here, we have investigated the functional consequences of the loss of E-cadherin in various cellular systems and transgenic mouse models and report that expression of the neuronal cell adhesion molecule (NCAM), a member of the immunoglobulin superfamily of genes, is upregulated concomitant with the loss of E-cadherin function. NCAM has been previously implicated in tumour progression and in lymph node metastasis, mainly by modulating b 1 -integrinmediated cell-matrix adhesion (Cavallaro et al, 2001; Christofori, 2003) . In neurons, NCAM triggers distinct signal-transduction pathways. Within lipid rafts, NCAM associates with and activates p59
Fyn kinase leading to the phosphorylation of focal adhesion kinase (FAK) and focal adhesion assembly, whereas in the non-raft compartment NCAM facilitates fibroblast growth factor receptor (FGFR)-activated signalling (Beggs et al, 1997; Niethammer et al, 2002) . Here, we demonstrate that the upregulation of NCAM expression is a direct result of the loss of adherens junctions. As a consequence, NCAM clusters in lipid rafts together with p59
Fyn , leading to FAK phosphorylation and focal adhesions assembly, activities required for cell motility and EMT.
Results

EMT induced by the loss of E-cadherin
We have employed several different experimental systems to investigate the functional impact of the loss of E-cadherin function on cell behaviour and cell signalling. First, TGFb treatment of NMuMG murine mammary gland epithelial cells, a well-characterized EMT model, induced a loss of E-cadherin expression accompanied by a complete EMT (Miettinen et al, 1994; Bhowmick et al, 2001 ) ( Figure 1A ). Second, shRNA-mediated knock down of E-cadherin in MCF7 human epithelial breast carcinoma cells substantially reduced E-cadherin expression (MCF7-shEcad; Figure 1A and B). Third, genetic ablation of E-cadherin function was achieved by establishing a cell line from mammary tumours of MMTVNeu transgenic mice (Muller et al, 1988) , in which both E-cadherin alleles were flanked by LoxP recombination sites (MTflEcad cells) (Derksen et al, 2006) . Expression of Crerecombinase in MTflEcad cells led to a complete abrogation of E-cadherin expression (MTdeltaEcad; Figure 1A and B).
The lack of E-cadherin expression in both MCF7-shEcad and MTflEcad cells resulted in a loss of epithelial morphology and a gain of a fibroblast-like appearance ( Figure 1A ). Reduced expression of E-cadherin in MCF7 cells was accompanied by decreased expression of other epithelial markers, such as b-catenin, and an increased expression of the mesenchymal markers N-cadherin and vimentin. The lack of E-cadherin in MTflEcad cells induced only N-cadherin expression, without any upregulation of vimentin or loss of b-catenin ( Figure 1B) . Furthermore, MCF7-shECad cells exhibited a eight-fold increase in cell motility and a threefold increase in invasiveness, whereas MTdeltaEcad cells only displayed a 2.5-fold elevated motility but no increased invasiveness (Supplementary Figure S1A and B). These data indicate that removal of E-cadherin can induce either a bona fide EMT (MCF7-shEcad) or merely a 'cadherin-switch' in the absence of a full EMT (MTdeltaEcad). Notably, cell proliferation was diminished upon E-cadherin depletion in all experimental systems tested (Supplementary Figure S1C) .
EMT induces NCAM expression
Gene expression profiling experiments and quantitative RT-PCR analysis comparing NMuMG, MCF7 and MTflEcad cells before and after the loss of E-cadherin function revealed that the expression of NCAM was significantly upregulated upon loss of E-cadherin expression in TGFb-treated NMuMG, MCF7-shEcad and MTdeltaEcad cells ( Figure 1C ). Immunoblotting analysis confirmed upregulated expression of the 140 kDa isoform of NCAM (NCAM140) in comparison to the E-cadherin-expressing cells ( Figure 1B ). NCAM mRNA upregulation was already detected 6 h after TGFb treatment of NMuMG cells, and an increase in NCAM protein levels was observed 24 h after TGFb treatment ( Figure 1D and E), indicating that the upregulation of NCAM expression is an early event upon loss of E-cadherin function and EMT. Ablation of E-cadherin by treatment of MTflEcad cells with recombinant Cre recombinase protein carrying a HIV-Tat cell entry peptide resulted in the concomitant loss of E-cadherin expression with the gain of NCAM expression, demonstrating that NCAM expression is upregulated by the loss of E-cadherin without any additional TGFb stimulation (Supplementary Figure S2B) . Also in HEK293 cells, mesenchymal phenotype cells that expressed low levels of E-cadherin, shRNA-mediated ablation of E-cadherin expression resulted in an elongated cell shape with increased motility and an upregulation of NCAM expression (Supplementary Figure  S3A-C) .
Next, we investigated the effect of loss of E-cadherin expression on NCAM gene promoter activity by CAT reporter assays. Utilizing DNA sequences of the NCAM gene promoter region either 1 kb (DSsp) or 647 bp (DNdeI) upstream of the transcriptional start site (Boras and Hamel, 2002) , TGFb treatment of NMuMG cells ( Figure 1F ) or ablation of Ecadherin expression in MCF7 cells (Supplementary Figure  S2A) provoked a significant increase in NCAM promoter reporter activity. It has been recently reported that Smad4-depleted NMuMG cells (NMuMG-shSmad4) maintain an epithelial morphology upon TGFb treatment (Deckers et al, 2006) . Consistent with this report, NMuMG-shSmad4 cells still expressed high levels of E-cadherin after 3 days of TGFb treatment, but only low levels of NCAM and N-cadherin in comparison to Smad4-expressing NMuMG-shControl cells ( Figure 1G ). These results indicate that Smad4-mediated signal transduction has a critical function in the induction of NCAM gene expression during TGFb-induced EMT.
To investigate whether NCAM upregulation also occurs in vivo, we crossed mice carrying LoxP-flanked conditional alleles of the E-cadherin gene (Derksen et al, 2006) with Rip1Cre mice in which Cre-recombinase was specifically expressed in b-cells of the pancreatic islets of Langerhans (Ahlgren et al, 1998) . Despite the low constitutive expression of NCAM in islet cells of normal control mice (Esni et al, 1999) , b-cells that upon successful recombination had lost E-cadherin expression exhibited significantly higher levels of NCAM at their cell surface (Supplementary Figure  S4) . Taken together, these data indicate that the loss of E-cadherin causes increased NCAM gene expression in vivo and in vitro.
NCAM is required for EMT
We next assessed whether increased NCAM levels were required for epithelial cells to undergo EMT. Three murine NCAM-specific siRNAs (simNCAM1, 2 and 3) efficiently downregulated NCAM mRNA and protein levels in NMuMG cells in comparison to control NCAM-mismatch-siRNA (siControl)-transfected cells (Figure 2A and B). NCAM-depleted NMuMG cells failed to undergo EMT and to upregulate the mesenchymal marker N-cadherin upon TGFb treatment, whereas siControl-transfected NMuMG cells readily converted to mesenchymal cells, indicating that NCAM is required for EMT to occur (Figure 2A and C) . Notably, ablation of NCAM expression in NMuMG cells, which after 13 days of TGFb treatment had undergone full EMT, led to a reversion of EMT, with characteristic polarized epithelial cell morphology. This morphological change was accompanied by an increase in E-cadherin expression and a decrease in N-cadherin expression, demonstrating that NCAM is not only required for the initiation but also for the maintenance of EMT in NMuMG cells ( Figure 2D ).
To investigate the role of NCAM in tumours undergoing EMT in vivo, we analysed E-cadherin expression during tumour progression in the Rip1Tag2 (RT2) transgenic mouse model of pancreatic b-cell carcinogenesis (Hanahan, 1985) , either wild type for NCAM expression or in a NCAM knockout background (RT2;NCAM þ / þ and RT2;NCAMÀ/À, respectively; Perl et al, 1999) . In wild-type RT2, the tumour areas showing downregulation of E-cadherin expression exhibited significantly higher intensities of diffuse NCAM-specific fluorescence staining at cell-cell contacts ( Figure 2E ). In contrast, in the absence of NCAM expression, 75% of the invasive carcinomas of RT2;NCAMÀ/À mice showed high levels of E-cadherin expression ( Figure 2F ; Po0.0001, Fisher's exact test). Altogether, these results indicate that ablation of NCAM expression prevents EMT and E-cadherin loss in vitro and in vivo. 
NCAM is sufficient to induce hallmarks of EMT
We next examined whether NCAM was able to induce EMT in epithelial cells. Ectopic expression of NCAM induced cell death in NMuMG as well as in MCF7 cells, as reported earlier with other EMT regulators (Mani et al, 2007) . We thus established several independent clones of MDCK epithelial cells expressing NCAM140 ( Figure 3A) . Notably, NCAMexpressing MDCK cells formed numerous foci on top of the confluent cell monolayer, a feature that was not observed in control-transfected cells ( Figure 3B ). Under sparse conditions, NCAM-expressing cells scattered and did not form cell-cell contacts, whereas control MDCK cells formed small cell clusters ( Figure 3B ).
In heterogeneous populations of NCAM-expressing and non-expressing cells, the majority of the NCAM-expressing cells delaminated from the cellular monolayer and migrated (siControl) and or an NCAM-specific siRNA (simNCAM3). After 48 h, phase-contrast images were taken (left panels). NCAM, N-cadherin (Ncad) and E-cadherin (Ecad) expression levels were analysed by immunoblotting (right panel). Antibodies against vinculin were used as a loading control. (E) Immunofluorescence staining for E-cadherin (red) and NCAM (green) on pancreatic sections from Rip1Tag2 mice. Lower panel: quantification of NCAM fluorescence in cell-cell junctions from E-cadherin-positive cells or E-cadherin-negative cells (each n ¼ 40) shows increased expression in cells that have lost E-cadherin (*Po0.0001, unpaired t-test). Blue DAPI staining visualizes nuclei. (F) Immunofluorescence staining for E-cadherin (red) on pancreatic sections from Rip1Tag2;NCAM þ / þ (upper panels), Rip1Tag2;NCAMÀ/À (lower panels) and Rip1Tag2 mice (right panels). Note that in contrast to carcinomas of Rip1Tag2;NCAM þ / þ mice, E-cadherin expression is maintained in carcinomas of Rip1Tag2;NCAMÀ/À mice. Blue DAPI staining visualizes nuclei. Ex, exocrine tissue; Tu, tumour tissue. on top of neighbouring epithelial cells ( Figure 3C ). In the NCAM-expressing cells, adherens junction proteins, such as b-catenin and E-cadherin, were undetectable ( Figure 3C ), whereas N-cadherin expression was increased ( Figure 3D ). These results indicate that NCAM is able to induce morphological and molecular changes representing typical hallmarks of EMT in MDCK cells (shown here) and also in E-cadherin-transfected fibroblastoid L cells (Esni et al, 1999) .
NCAM induces focal adhesion assembly
As we had shown earlier that NCAM was able to modulate b 1 -integrin-mediated cell-matrix adhesion (Cavallaro et al, 2001) , we compared control-and NCAM-depleted cells for their ability to spread on fibronectin-coated culture dishes. Cell spreading was significantly reduced in TGFb-treated NMuMG cells upon NCAM removal ( Figure 4A and B) . Furthermore, cell spreading of TGFb-treated, 'mesenchymal' NMuMG cells could be repressed by neutralizing antibodies against b 1 -integrin ( Figure 4A ), whereas spreading of nontreated epithelial NMuMG cells was unaffected ( Figure 4B ). Consistent with this notion, numerous focal contacts were observed at the ventral surface of TGFb-treated NMuMG cells in comparison to their epithelial counterparts ( Figure 4C ), and cells undergoing EMT exhibited increased amounts of phosphorylated FAK and paxillin and enhanced cell spreading ( Figure 4D ). Such TGFb-mediated focal adhesion assembly as well as FAK phosphorylation was not observed in NCAM-depleted NMuMG cells ( Figure 4C and D) . In a time course of mesenchymal cell spreading, FAK was constantly phosphorylated, suggesting a high stability of the focal adhesions, whereas in NCAM-depleted cells, the levels of FAK phosphorylation oscillated, indicating a high turnover of focal adhesions ( Figure 4E ).
Transwell migration assays revealed a significantly higher chemotactic migration of TGFb-treated, simNCAM-transfected NMuMG cells as compared with TGFb-treated, siControl-transfected cells ( Figure 4F ). Moreover, NCAMdepleted TGFb-treated NMuMG cells migrated significantly faster in scratch wounding assays than NCAM-expressing control cells (Supplementary Figure S5) . However, adhesion assays performed to quantify stable matrix attachment of cells independent of their spreading capacity did not reveal any differences between NCAM-expressing and non-expressing cells (data not shown). These data suggest that NCAM has a critical function in focal adhesion assembly and turnover, rather than in modulating the strength of cell-matrix adhesion.
NCAM re-localizes into lipid rafts upon EMT
In neurons, it has been reported that a signalling complex between NCAM, p59
Fyn and FAK is formed upon homophilic NCAM-NCAM interactions, and that NCAM-mediated signalling through p59
Fyn depends on its localization to lipid rafts (Beggs et al, 1997; Niethammer et al, 2002) . Indeed, TGFb treatment of NMuMG cells led to increased phosphorylation 
of p59
Fyn ( Figure 5A ). Immunofluorescence analysis revealed that in TGFb-treated NMuMG cells, NCAM was predominantly localized in the junctions between cells and in focal plasma membrane areas ( Figure 5B , upper panels) where it colocalized with FAK ( Figure 5B , lower panels). Sucrose gradient density centrifugation experiments demonstrated that the low levels of NCAM present in epithelial NMuMG cells were found exclusively in the detergent-soluble protein fractions ( Figure 5C ). In contrast, in TGFb-treated NMuMG cells, a substantial proportion of the high levels of NCAM were also detected in the top fractions of the gradient ( Figure 5C ), indicating an association of NCAM with detergent-resistant lipid rafts. FAK and phosphorylated p59
Fyn were also found in the NCAM-containing lipid raft fractions of the gradient. Disruption of lipid rafts by cholesterol depletion with methyl-b-cyclodextrin (M-b-CD) completely impaired the formation of NCAM clusters in TGFb-treated NMuMG cells, whereas the actin cytoskeleton and cell shape remained largely unaffected ( Figure 5D , data not shown). These experiments indicate that a subset of NCAM shifts its localization to p59
Fyn /FAK containing lipid rafts upon the transition to a mesenchymal phenotype.
As NCAM has been shown to physically associate with FGFR, PLCg and cortactin outside lipid rafts (Cavallaro et al, 2001) , we next assessed whether these NCAM-containing signalling complexes were unchanged during EMT. Immunoprecipitation experiments with antibodies against NCAM revealed that FGFR2 was found associated with NCAM regardless of TGFb treatment of NMuMG cells. In contrast, the signalling effectors PLCg and cortactin co-immunoprecipitated with NCAM exclusively in untreated epithelial NMuMG cells and not in TGFb-treated 'mesenchymal' NMuMG cells ( Figure 5E ). These data suggest that during TGFb-induced EMT of NMuMG cells, NCAM changes its subcellular localization and its signalling partners, which in turn leads to focal adhesion stabilization.
NCAM mediates focal adhesion assembly in various EMT systems
To assess whether NCAM exerts this critical function also during EMT in other experimental systems, its expression was ablated in MCF7-shEcad, MTdeltaEcad and HEK293 cells by transfection of specific murine or human siRNAs (Supplementary Figure S6A-D) . In MCF7-shEcad cells depleted from NCAM, a loss of neurite extensions was observed ( Figure 6A ), an established hallmark of NCAM function (Cavallaro et al, 2001) . In contrast, no obvious morphological changes were observed in MTdeltaEcad cells upon NCAM depletion (data not shown), suggesting that these cells were irreversible in their mesenchymal phenotype Fyn (arrow) only in the absence of E-cadherin, and PLCg only in the presence of E-cadherin. Vinculin was used as a loading control. The asterisk indicates immunoglobulin heavy chain.
(note that these cells carry an irreversible deletion of the E-cadherin gene).
As observed in TGFb-treated NMuMG cells, numerous focal contacts were observed at the ventral surface of MTdeltaEcad and MCF7-shEcad cells ( Figure 6B and data not shown). Consistent with this observation, increasing amounts of phosphorylated FAK and paxillin were observed in cells in MTdeltaEcad in comparison to their epithelial counterparts ( Figure 6C ). Upon depletion of NCAM from MTdeltaEcad cells, FAK phosphorylation was rapidly lost during cell spreading, whereas it remained constant in control cells ( Figure 6D) . As a consequence, cell spreading of NCAM-depleted MCF7-shEcad, MTdeltaEcad and HEK293 cells were reduced ( Figure 6E and data not shown) . Notably, phosphorylation of paxillin was unaffected by the presence or absence of NCAM, indicating that paxillin phosphorylation is mediated by an NCAM-independent pathway ( Figures 4C and D, and 6D ).
Comparable to NMuMG cells, in HEK293 cells, NCAM localization also shifted from non-lipid raft to lipid raft membrane fractions upon loss of E-cadherin ( Figure 6F ). Consistent with this observation, disruption of lipid rafts by cholesterol depletion with M-b-CD completely impaired the formation of NCAM clusters in HEK293-shEcad and MTdeltaEcad cells ( Figure 6F and data not shown). Forced, inducible expression of NCAM in HEK293 cells resulted in the translocation of a subset of NCAM into lipid rafts, demonstrating that increased levels of NCAM protein mediate its translocation to lipid rafts and that the loss of E-cadherin is not necessarily required for this process (Supplementary Figure S7) .
Immunoprecipitation experiments revealed that in E-cadherin-deficient HEK293-shEcad cells, the high levels of NCAM associated with p59
Fyn , an interaction that could not be detected in control cells expressing low levels of NCAM ( Figure 6G ). Similar to TGFb-treated NMuMG cells, in HEK293 cells NCAM associated with PLCg only in the presence of E-cadherin ( Figure 6G ). These results indicate that, upon loss of E-cadherin function, NCAM ceases to associate with PLCg and cortactin and a subset of NCAM protein re-localizes to lipid rafts where it binds to p59
Fyn .
Expression of NCAM in human and mouse tumours
We next determined whether upregulated NCAM expression was also observed in E-cadherin-negative cancer cells in vivo.
NCAM and E-cadherin expression were analysed by immunohistochemical staining of tumour tissue from a recently published mouse model of lobular breast carcinogenesis, in which mice carrying LoxP-flanked alleles of the p53 gene (Trp53F) were crossed with keratin14 gene promoter-Cre recombinase mice (K14-Cre) and with mice carrying LoxP-flanked alleles of E-cadherin (EcadF/F; Derksen et al, 2006) . In E-cadherin-expressing tumours (K14-Cre;Trp53F/ F;EcadF/ þ ), E-cadherin was expressed at the membrane of most tumour cells ( Figure 7A ), whereas NCAM could only be detected in large blood vessels of the surrounding fat or muscle tissue and in the basal layer of the epidermis ( Figure 7A,b) . In contrast, in tumours of K14-Cre;Trp53F/ F;EcadF/F mice, E-cadherin expression was efficiently ablated ( Figure 7A,c ), yet NCAM expression was now detectable at varying intensities in tumour cells ( Figure 7A,d) . In particular, cells within invasive tumour fronts displayed significant NCAM expression, for example at the interface between tumours and subcutaneous myocytes and Figure 7 NCAM is upregulated in E-cadherin-negative tumours. (A) Serial histological sections from breast tumours of K14-Cre;Trp53F/F mice expressing E-cadherin (Ecad F/ þ ) or deficient in E-cadherin expression (Ecad F/F) were stained with antibodies against E-cadherin (a, c) and NCAM (b, d-f) . NCAM is absent in E-cadherin-expressing tumour cells (a, b). In contrast, NCAM is expressed in tumours that have lost Ecadherin expression (c, d) . NCAM is predominantly expressed on the invasive front of E-cadherin-negative tumours at the interphase between tumour cells and myocytes (e) or adipocytes of the skin (f). Disseminated tumour cells in the stroma (indicated by arrows in e) also display strong NCAM staining. Inserts represent higher magnifications of the respective sections. Size bars ¼ 100 mm. (B) Serial histological sections from a human patient neuroendocrine carcinoid were stained with antibodies against E-cadherin (a-d) and NCAM (e, f). NCAM is not expressed in E-cadherin-positive, differentiated cancer cells, whereas NCAM is expressed in invasive cancer cells with reduced E-cadherin expression. Morphological structures are marked for orientation. Size bars ¼ 200 mm.
adipocytes, as well as in disseminated tumour cells ( Figure 7A ,e and f).
We next assessed NCAM expression in human cancers by immunohistochemical staining of multi-tissue arrays containing 39 different human cancer types and corresponding 22 normal tissues. Depending on availability, between 5 and 50 samples per cancer type were analysed. A particular strong upregulation of NCAM was observed in neuroendocrine tumours, including small-cell lung cancer (35 of 43 patients, Po0.001, Fisher's exact test) and intestinal carcinoids (33 of 44 patients, Po0.001, Fisher's exact test), cancer types known to lose E-cadherin expression during tumour progression (Salon et al, 2004) . Staining of serial histological sections of a human intestinal neuroendocrine carcinoid revealed expression of NCAM predominantly in the invasive cancer cells of the tumour with low or no E-cadherin expression, whereas NCAM was not found to be expressed in the Ecadherin positive, differentiated compartments of the tumour ( Figure 7B ). These results indicate that NCAM is upregulated upon loss of E-cadherin function in certain types of human cancers.
Discussion
We have employed cellular experimental systems, transgenic mouse models and patient biopsies to investigate how the loss of E-cadherin function contributes to tumour progression. Notably, E-cadherin depletion in cultured cells in vitro leads to increased expression of the cell adhesion molecule NCAM. A comparable NCAM upregulation is also observed in transgenic mouse models of malignant insulinoma and lobular breast carcinoma and in human small-cell lung cancer and intestinal carcinoids, where a loss of E-cadherin and a gain of mesenchymal markers have been previously implicated in tumour progression (Perl et al, 1998; Salon et al, 2004; Derksen et al, 2006, this paper) . Interestingly, expression of L1, a close relative of NCAM, is also observed in E-cadherin-negative cells of the invading tumour front, for example in colorectal cancer (Gavert et al, 2005) .
The molecular mechanisms underlying the regulation of NCAM gene expression during EMT are the focus of intense investigations in our laboratory. Here, we have assessed the functional contribution of upregulated NCAM expression to EMT. In the tumour progression models employed here, NCAM is found in two distinct complexes: in the presence of E-cadherin, low levels of NCAM localize outside lipid rafts and associate with FGFR, PLCg and cortactin. Upon loss of E-cadherin function, NCAM expression levels are increased, and a subset of NCAM protein translocates to lipid rafts, where it associates with p59 Fyn . Subsequent phosphorylation and activation of p59
Fyn and its effector substrate FAK result in the stabilization of b 1 -integrin-mediated focal adhesions and increased cell spreading and migration (Figure 8 ). On the other hand, FGFR transmits NCAM-dependent and NCAM-independent signals: NCAM-mediated activation of FGFR leads to the activation of PLCg and through the Raf-kinase PKCbII to sustained MAPK activation and increased cell adhesion. In contrast, stimulation of FGFR by FGFs activates PLCg/PKCa and Ras/Raf/MAPK signalling pathways and promotes cell adhesion and proliferation (Francavilla et al, 2007; Figure 8 ). Thus, loss of E-cadherin affects the nature of NCAM-mediated signal transduction by inducing NCAM gene expression and by changing NCAM's subcellular localization. Forced expression of NCAM also resulted in its translocation to lipid rafts even in Figure 8 NCAM upregulation leads to a functional switch. A working model of the molecular mechanisms underlying the change in NCAM subcellular localization and its interacting partners during EMT is depicted. In epithelial cells, low levels of NCAM form a complex with FGFR and PLCg leading to the activation of the Raf-kinase PKCbII and thus to a sustained activation of the MAPK pathway and cell adhesion. Upon loss of E-cadherin function during EMT, NCAM is highly expressed, and a subset localizes to lipid rafts where it associates with p59
Fyn , leading to FAK phosphorylation, focal adhesion assembly and cell migration. Both NCAM-mediated signalling pathways are required for neurite outgrowth. In contrast, FGF-induced stimulation of FGFR results in PLCg-mediated activation of PKCa and a short pulse activation of the Ras/ Raf/MAPK pathway resulting in cell adhesion and proliferation. FGF-induced signalling is over-ruled by the NCAM-mediated signals (Cavallaro et al, 2001; Francavilla et al, 2007) . the presence of E-cadherin, indicating that the levels of NCAM proteins determine its subcellular localization and thus its signalling qualities (Supplementary Figure S7) . It is interesting to note that NCAM is a haplo-insufficient gene, indicating that NCAM gene dosage has a critical function in development and disease (Esni et al, 1999; Perl et al, 1999) . Our results may provide a biochemical explanation for this gene dosage effect. The results also substantiate findings in neurons, where it has been demonstrated that NCAM140 localized in membrane compartments outside lipid rafts binds and stimulates FGFR through its fibronectin type III domains, which in turn activates PLCg and MAPK signalling pathways (Doherty and Walsh, 1996; Niethammer et al, 2002) . In contrast, when situated within lipid rafts, NCAM associates with p59
Fyn and activates FAK kinase-mediated signalling (Beggs et al, 1997; Niethammer et al, 2002) .
Apparently, NCAM expression has an essential function in mesenchymal cell motility as characterized by the formation of b 1 -integrin-dependent focal adhesions. We have shown earlier that the genetic ablation of NCAM gene expression results in the loss of b 1 -integrin activation (Cavallaro et al, 2001) and that ablation of NCAM or b 1 -integrin leads to reduced tumorigenicity of tumour cells . Here, we demonstrate that, after loss of E-cadherin function and gain of NCAM expression during EMT, phosphorylated FAK is stabilized and b 1 -integrin-mediated cell spreading is enhanced. In contrast, in epithelial cells, FAK phosphorylation has a high turnover, very few focal adhesions are detected, and cell spreading is slow and largely b 1 -integrin independent.
On the basis of the data presented, we conclude that the loss of E-cadherin, among many other molecular consequences, induces upregulated expression of the NCAM gene. As a result, increased levels of NCAM localize to lipid rafts and through p59
Fyn induce the formation of focal adhesions and integrin-dependent mesenchymal cell migration and invasion. The correlation between the loss of E-cadherin and the gain of expression of NCAM and other Ig domain adhesion molecules in specific human cancer types and mouse models of carcinogenesis indicate that these molecular pathways have a critical function in malignant tumour progression and metastasis and, thus, warrant further investigation.
Materials and methods
Reagents and antibodies
Mouse NCAM-Fc (20 mg/ml) was a gift from U Cavallaro (IFOM, Milano, Italy). TGFb: R&D Systems (Abingdon, UK). Antibodies: anti-a-actin (Abcam, Cambridge, UK), anti-E-cadherin (for immunoblotting), anti-pY397FAK, anti-FAK, anti-p-paxillin, antipY528p59
Fyn (BD Transduction Laboratories, Allschwil, Switzerland), anti-E-cadherin (for immunostaining; Zymed, San Diego, CA), anti-vinculin N-19 and anti-hNCAM 123C3 (Santa Cruz Biotechnology, Heidelberg, Germany), anti-vimentin clone V9, anti-b-catenin and anti-hNCAM OB-11 (Sigma, Basel, Switzerland), anti-b 1 -integrin MAB2253Z (Millipore, Volketswil, Switzerland), anti-FGFR2 C-17, anti-cortactin 4F11, anti-PLCg and anti-p59 Fyn (Upstate Biotechnology, Lake Placid, NY), anti-murine NCAM 5B8 (immunoblotting and immunofluorescence), anti-NCAM 13 (immunoprecipitation; BD Transduction Laboratories) and anti-Ncadherin (Takara Biomedicals, Tokyo, Japan).
Cells and cell lines
A subclone of NMuMG cells (NMuMG/E9; hereafter NMuMG) expressing E-cadherin has been described earlier (Maeda et al, 2005) . MDCKII, NMuMG, HEK293 and MCF7 cells were cultured in DMEM supplemented with glutamine, penicillin, streptomycin and 10% FCS (Sigma). Oligonucleotides (Supplementary Table S1 ) were annealed and inserted into the pSUPER-retro-neo vector (OligoEngine, Seattle, WA) to generate pSUPER-Ecad-shRNA and pSUPERCont-shRNA. MCF7 and HEK293 cells stably transfected with pSuperRetro-Ecad-shRNA (shEcad) and pSuperRetro-mNCAMshRNA (sh-cont) and MDCKII cells stably transfected with NCAM140 expression vectors were selected in G418. NMuMGshSmad4 and NMuMG-shCont were obtained from P ten Dijke (Leiden University Medical Center, The Netherlands; Deckers et al, 2006) . TGFb treatment of NMuMG cells was performed without serum deprivation, and TGFb was replenished every 3 days. MTflEcad cells were established from a mammary gland tumour isolated from an MMTV-Neu mouse (Muller et al, 1988) crossed with EcadF/F mice (Derksen et al, 2006) . To establish the MTflEcadCre cell line, MTflEcad cells were infected with LZRSpBMN retroviral vector expressing Cre-IRES-GFP. After infection, GFPexpressing cells were sorted by FACS. hNCAM and mNCAM siRNAs were purchased from Invitrogen (Stealth siRNA duplex oligoribonucleotides; Supplementary Table S1 ). Transfections with LipofectAMINE RNAiMAX (Invitrogen) were performed according to the manufacturer's instructions. Total cell lysates, immunoblots and immunofluorescence experiments were performed as described earlier (Wicki et al, 2006) . Depending on the species origin of antibodies, immunoblots were either probed sequentially or on multiple membranes. Adobe Photoshop has been used to excise the relevant portion of the immunoblots from the original scans of X-ray films exposed to chemiluminescence visualization of specific proteins, as indicated by black frames in the figures.
Migration and invasion assays
Cell migration was determined in a modified two-chamber migration assay (pore size: 8 mm; Falcon BD, Franklin Lakes, NJ). For invasion assays, membranes were coated with 20 ml of a 2.5 mg/ ml solution of Matrigel (Falcon BD). For both assays, 10 5 cells were seeded in 1% fetal calf serum/DMEM (Sigma) in the upper chamber, and the lower chamber was filled with 10% fetal calf serum/DMEM. After 24 h incubation at 371C, cells in the upper chamber were carefully removed with a cotton swab and the cells that had traversed the membrane were fixed in 4% paraformaldehyde/HBS-Ca 2 þ , stained with crystal violet (0.5% in 20% methanol) and counted.
Cell spreading assay
To quantify cell spreading, cells were plated on a plastic culture dish, and 30 min after seeding the medium was changed to eliminate unattached cells. Cells were incubated at 371C and counted in regular intervals in four independent experiments. In cases where b 1 -integrin blocking antibodies were used, cells were incubated for 30 min with 100 mg/ml mouse IgG or anti-b 1 -integrin antibodies prior to seeding.
In vitro wounding assay A scratch wound was generated using a 200 ml pipette tip on confluent cell monolayers in a six-well culture plates in 10% serum containing DMEM medium (Sigma, St Louis, MO). Cells were then washed with fresh medium to remove floating cells. Microphotographs were taken at different time points.
Quantitative RT-PCR Total RNA was prepared using Trizol (Invitrogen), reverse transcribed with M-MLV reverse transcriptase RNAse (HÀ) (Promega, Wallisellen, Switzerland), and transcripts were quantified by PCR using SYBR green PCR MasterMix (Applied Biosystems, Rotkreuz, Switzerland) and the primers indicated in Supplementary  Table S1 . Human or mouse riboprotein L19 primers were used for normalization. PCR assays were performed in triplicate, and fold induction was calculated against control-treated cell lines using the comparative C t method (DDC t ).
CAT assays
NMuMG cells were transfected with DNde and DSsp NCAM-CAT reporter constructs (Boras and Hamel, 2002) and treated with TGFb for 6 days. CAT assays were performed using the CAT Enzyme Assay System (Promega). CAT activities were normalized relative to co-transfected control luciferase activities.
